mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT.

[1]  Prashant Mishra,et al.  The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility , 2017, Nature Communications.

[2]  C. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[3]  Karen H. Vousden,et al.  Serine and one-carbon metabolism in cancer , 2016, Nature Reviews Cancer.

[4]  J. Rabinowitz,et al.  mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1. , 2016, Molecular cell.

[5]  A. Richardson,et al.  Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine , 2016, Cell.

[6]  B. Kennedy,et al.  The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. , 2016, Cell metabolism.

[7]  K. Akashi,et al.  The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-). , 2016, Cancer research.

[8]  C. Thompson,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[9]  P. Mischel,et al.  mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment , 2015, Brain pathology.

[10]  D. Tuveson,et al.  The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1 , 2015, Cell.

[11]  Webster K. Cavenee,et al.  Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance , 2015, Proceedings of the National Academy of Sciences.

[12]  A. Lahti,et al.  SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma , 2015, Science Translational Medicine.

[13]  Y. Bhutia,et al.  Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. , 2015, Cancer research.

[14]  P. Rada,et al.  Melatonin–sulforaphane hybrid ITH12674 induces neuroprotection in oxidative stress conditions by a ‘drug–prodrug’ mechanism of action , 2015, British journal of pharmacology.

[15]  M. Sugimoto,et al.  Cystathionine Is a Novel Substrate of Cystine/Glutamate Transporter , 2015, The Journal of Biological Chemistry.

[16]  María Martín,et al.  UniProt: A hub for protein information , 2015 .

[17]  M. Dreyer,et al.  Discovery of N-[4-(1H-Pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides as Highly Active and Selective SGK1 Inhibitors. , 2015, ACS medicinal chemistry letters.

[18]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[19]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[20]  J. Aramburu,et al.  Transcriptional regulation of the stress response by mTOR , 2014, Science Signaling.

[21]  Feng Liu,et al.  mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. , 2013, Cell metabolism.

[22]  J. Gray,et al.  Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. , 2013, Cancer cell.

[23]  Devin K. Schweppe,et al.  Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. , 2013, Journal of proteomics.

[24]  Dudley Lamming,et al.  A Central role for mTOR in lipid homeostasis. , 2013, Cell metabolism.

[25]  Christian M. Metallo,et al.  Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells , 2013, Nature.

[26]  P. Kalivas,et al.  The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. , 2013, Antioxidants & redox signaling.

[27]  M. Peng,et al.  Toward a comprehensive characterization of a human cancer cell phosphoproteome. , 2013, Journal of proteome research.

[28]  Johannes Griss,et al.  The Proteomics Identifications (PRIDE) database and associated tools: status in 2013 , 2012, Nucleic Acids Res..

[29]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[30]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[31]  K. Lage,et al.  Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues , 2012, Nature Communications.

[32]  Ivan Babic,et al.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. , 2011, Cancer discovery.

[33]  S. Gygi,et al.  Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling , 2011, Science.

[34]  D. Sabatini,et al.  The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling , 2011, Science.

[35]  M. Ohmura,et al.  CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. , 2011, Cancer cell.

[36]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[37]  D. Sabatini,et al.  Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. , 2010, Journal of medicinal chemistry.

[38]  D. Sabatini,et al.  mTOR signaling at a glance , 2009, Journal of Cell Science.

[39]  J. Asara,et al.  Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1 , 2009, Molecular and Cellular Biology.

[40]  E. Jacinto,et al.  TOR regulation of AGC kinases in yeast and mammals. , 2008, The Biochemical journal.

[41]  M. Mann,et al.  A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC) , 2006, Nature Protocols.

[42]  T. Cloughesy,et al.  Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. , 2006, Cancer research.

[43]  H. Sontheimer,et al.  Inhibition of Cystine Uptake Disrupts the Growth of Primary Brain Tumors , 2005, The Journal of Neuroscience.

[44]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[45]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[46]  M. Palacín,et al.  Membrane Topology of System Xc- Light Subunit Reveals a Re-entrant Loop with Substrate-restricted Accessibility* , 2004, Journal of Biological Chemistry.

[47]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[48]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[49]  N. Bruchovsky,et al.  Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc− cystine transporter: a new action for an old drug , 2001, Leukemia.

[50]  Y. Kanai,et al.  Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. , 2001, Biochimica et biophysica acta.

[51]  G. Borsani,et al.  Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system xc– , 2001, Pflügers Archiv.

[52]  F. Coe,et al.  A modified cyanide-nitroprusside method for quantifying urinary cystine concentration that corrects for creatinine interference. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[53]  Jie Chen,et al.  The FKBP12-Rapamycin-binding Domain Is Required for FKBP12-Rapamycin-associated Protein Kinase Activity and G1 Progression* , 1999, The Journal of Biological Chemistry.

[54]  P. Cohen,et al.  Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase‐1 and p70 S6 kinase , 1996, FEBS letters.

[55]  H. Nawashiro,et al.  Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. , 2013, Neurosurgery.

[56]  Hideyo Sato,et al.  The oxidative stress-inducible cystine/glutamate antiporter, system xc−: cystine supplier and beyond , 2011, Amino Acids.

[57]  D. Alessi,et al.  The nuts and bolts of AGC protein kinases , 2010, Nature Reviews Molecular Cell Biology.

[58]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[59]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.